The Swiss Medical Board has ceased its activities.

The website remains available but is no longer updated after June 30, 2022.

DE | EN | FR

Clinical Effectiveness, Safety and Cost-Effectiveness of Chemotherapy or Radiotherapy plus Androgen Deprivation Therapy (ADT) versus ADT Alone in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer

Significant advances have been made in the treatment of prostate cancer in recent years, significantly improving the prognosis of patients with severe disease. However, it was unclear whether any of the new treatment options are superior to the others and what the cost-benefit ratio is. In its newly published report, the Swiss Medical Board gives all options a positive rating.